STOCK TITAN

Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Quotient Limited (NASDAQ:QTNT) will present at the Cowen 41st Annual Healthcare Conference on March 1, 2021, at 1:20 PM ET. The presentation will be available via live webcast on the company's investor relations page, with a replay archived for 90 days. Quotient specializes in transfusion diagnostics, aiming to transform diagnostics practices through its innovative MosaiQ technology, which offers fully automated, consolidated testing. Their MosaiQ COVID-19 Antibody Microarray has earned CE marking and FDA Emergency Use Authorization.

Positive
  • None.
Negative
  • None.

JERSEY, Channel Islands, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the Company will present at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 1:20pm ET.

A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.

Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26


FAQ

When will Quotient Limited present at the Cowen 41st Annual Healthcare Conference?

Quotient Limited will present on March 1, 2021, at 1:20 PM ET.

How can I watch the Quotient Limited presentation at the Cowen Conference?

The presentation will be available via live webcast on Quotient's investor relations page.

What is MosaiQ technology by Quotient?

MosaiQ is a proprietary multiplex microarray technology providing automated, consolidated testing solutions in diagnostics.

What COVID-19 diagnostic product does Quotient offer?

Quotient has developed the MosaiQ COVID-19 Antibody Microarray, which is CE marked and has received FDA Emergency Use Authorization.

Where are Quotient Limited's operations located?

Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland, and Newtown, Pennsylvania.

Quotient Ltd

NASDAQ:QTNT

QTNT Rankings

QTNT Latest News

QTNT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Eysins